Stent manufacturers always record stent shortening data while they do not record stent elongation data. The aim of this study is to identify both stent shortening and elongation occurring after deployment in the coronary arteries and know their percentage. The length of coronary stents was measured by intravascular ultrasound (IVUS) by (1) edge-to-edge (E-E) length, measured from the appearance of the first distal strut to the last proximal strut, and (2) area-to-area (A-A) length, measured from the first distal struts seen at more than one IVUS quadrant to the last proximal struts seen at more than one IVUS quadrant. Stent shortening was defined as both E-E and A-A lengths were shorter than the manufacturer box-stated length (shortened group). Stent elongation was defined as both E-E and A-A lengths were longer than the manufacturer box-stated length (elongated group), otherwise unchanged group. Consecutive 102 stents deployed in ischemic patients were included. Stent elongation was detected in 67.6% (69 stents), and shortening was detected in 15.7% (16 stents), while unchanged stents were detected in 16.7% (17 stents). Although the 3 groups had similar box-stated length and predicted foreshortened length, they had significantly different measurements by IVUS, p<0.001 for each comparison. Differences from box-stated length were 1.9±1.4mm, −1.4±0.4mm, and 0.4±0.3mm, respectively, p<0.001. The elongated group had significantly longer differences from the corresponding box-stated and predicted foreshortened lengths, while the shortened group had significantly shorter differences from the corresponding box-stated length and similar foreshortened length. By multinomial regression analysis, the plaque-media area and stent deployment pressure were the independent predictors of the stent length groups, p=0.015 and p=0.026, respectively. Change in stent length is not only shortening—as mentioned in the manufacturer documents—but also stent elongation. Stent elongation is dominant, and the most important predictors of longitudinal stent changes are plaque-media area and stent deployment pressure.

中文翻译：

---

纵向支架在冠状动脉内部署后的伸长或缩短：哪一个占主导地位？

支架制造商总是记录支架缩短数据，而他们不记录支架伸长数据。本研究的目的是确定在冠状动脉内部署后发生的支架缩短和伸长情况，并了解其百分比。冠状动脉支架的长度通过血管内超声（IVUS）通过以下方式测量：（1）边缘到边缘（EE）的长度，从第一个远端撑杆的外观到最后一个近端撑杆的外观，以及（2）面积到面积（AA）长度，从在一个以上IVUS象限处看到的第一个远侧支撑杆到在一个以上IVUS象限中看到的最后一个近侧支撑杆测得。缩短支架的定义是，EE和AA长度均短于制造商规定的长度（缩短组）。支架伸长定义为EE和AA长度均比制造商规定的长度（伸长组）长，否则不变。包括在缺血性患者中连续使用的102个支架。在67.6％（69个支架）中检测到支架伸长，在15.7％（16个支架）中检测到缩短，而在16.7％（17个支架）中检测到未改变的支架。尽管3组的盒式长度和预测的缩短长度相似，但通过IVUS进行的测量差异显着，每次比较p <0.001。与盒式长度的差异分别为1.9±1.4mm，-1.4±0.4mm和0.4±0.3mm，p <0.001。拉长的组与相应的盒式表示和预测的缩短长度的差异明显更长，而缩短组与相应的盒式长度和类似的缩短长度相比，差异明显缩短。通过多项式回归分析，斑块介质面积和支架展开压力是支架长度组的独立预测因子，分别为p = 0.015和p = 0.026。支架长度的变化不仅缩短（如制造商文档所述），而且缩短支架的伸长率。支架的伸长率占主导地位，而纵向支架变化的最重要预测指标是斑块-介质面积和支架展开压力。支架长度的变化不仅缩短（如制造商文档所述），而且缩短支架的伸长率。支架的伸长率占主导地位，而纵向支架变化的最重要预测指标是斑块-介质面积和支架展开压力。支架长度的变化不仅缩短（如制造商文档所述），而且缩短支架的伸长率。支架的伸长率占主导地位，而纵向支架变化的最重要预测指标是斑块-介质面积和支架展开压力。